Hermes-3細(xì)胞

細(xì)胞形態(tài)： **樣

**類(lèi)型： IgG2a

運(yùn)輸方式： 凍存運(yùn)輸

數(shù)量： 大量

ATCC Number： HB-9480?

生長(zhǎng)狀態(tài)： 懸浮生長(zhǎng)

是否是腫瘤細(xì)胞： 0

物種來(lái)源： 小鼠

Designations: Hermes-3

Hermes-3細(xì)胞Depositors: Stanford University Board of Trustees

Isotype: IgG2a

Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: suspension

Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)

Morphology: lymphoblast

Source: Cell Type: hybridoma: B lymphocyte;

Cellular Products: immunoglobulin; monoclonal antibody; against human Peyer's patch endothelial cells (CD44)

Permits/Forms: Hermes-3細(xì)胞In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Applications: The antibody specifically inhibits lymphocyte adhesion to human mucosal high endothelial venules (HEV).

It binds to an extracellular site on CD44, proximal to the hyaluronate binding site and distal to the sites of variant exon splicing.

Comments: Animals were immunized with.

Spleen cells were fused with myeloma cells.

The antibody specifically inhibits lymphocyte adhesion to human mucosal high endothelial venules (HEV).

It binds to an extracellular site on CD44, proximal to the hyaluronate binding site and distal to the sites of variant exon splicing.

It does not inhibit lymphocyte binding to hyaluronate.

Propagation: ATCC complete growth medium: HB101 medium, 100% - OR - RPMI 1640 medium, 90%; fetal bovine serum, 10%

Subculturing: Hermes-3細(xì)胞Medium Renewal: Every 2 to 3 days

Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.

References: 22068: Butcher EC. Method to control leukocyte extravasation. US Patent 5,403,919 dated Apr 4 1995

22799: Jalkanen S, et al. Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85-95-kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells. J. Cell Biol. 105: 983-990, 1987. PubMed: 2442176

22800: Picker LJ, et al. Monoclonal antibodies to human lymphocyte homing receptors define a novel class of adhesion molecules on diverse cell types. J. Cell Biol. 109: 927-937, 1989. PubMed: 2474557

23155: Vogel H, et al. H-CAM expression in the human nervous system: evidence for a role in diverse glial interactions. J. Neurocytol. 21: 363-373, 1992. PubMed: 1607880

23176: Jalkanen ST, et al. A lymphoid cell surface glycoprotein involved in endothelial cell recognition and lymphocyte homing in man. Eur. J. Immunol. 16: 1195-1202, 1986. PubMed: 2429846

23387: Butcher EC. Hermes-3細(xì)胞Specificity of leukocyte-endothelial interactions and diapedesis: physiologic and therapeutic implications of an active decision process. Res. Immunol. 144: 695-698, 1993. PubMed: 8159870

23473: Picker LJ, et al. Monoclonal antibodies against the CD44 [In(Lu)-related p80], and Pgp-1 antigens in man recognize the Hermes class of lymphocyte homing receptors. J. Immunol. 142: 2046-2051, 1989. PubMed: 2646376